It has been evident that the FRα-specific humanized mAb farletuzumab has strong tumor growth suppression in animal-based models of human solid tumors, and Lin and colleagues reported that such tumoricidal effects are exerted through antibody-dependent cellular cytotoxicity (ADCC) by conducting an investigation using mouse models of ovarian cancer (99). Here, FOLR1 is linked to neoplasm.